Skip Navigation
Menu
Letters |6 September 2005

Pegylated Interferon-α2b and Lamivudine in Hepatitis B e Antigen-Positive Chronic Hepatitis B

Martijn J. ter Borg, MD; Harry L.A. Janssen, MD, PhD

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
  • From Erasmus Medical Center Rotterdam, 3015 GD Rotterdam, the Netherlands.

    Potential Financial Conflicts of Interest: None disclosed.

×
FULL TEXT
TO THE EDITOR:
In Chan and colleagues' study of pegylated interferon in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (1), the sustained virologic response (HBeAg seroconversion and hepatitis B virus DNA level less than 500 000 copies/mL) was 36% after 32 weeks of therapy with pegylated interferon-α2b plus 52 weeks of lamivudine. This percentage is comparable with the HBeAg seroconversion rates in 2 global studies investigating combination therapy with pegylated interferon and lamivudine for 1 year (2, 3). In one of these studies, coordinated by our group (2), patients were treated for 52 weeks with pegylated interferon-α2b and lamivudine, and HBeAg seroconversion was achieved in 25% at the end of treatment. In the study by Lau and colleagues (3), patients were treated with pegylated interferon-α2a and lamivudine for 48 weeks and 24% experienced HBeAg seroconversion at the end of treatment.
FULL TEXT
PDF
Not Available
Citations
Citation

ter Borg MJ, Janssen HL. Pegylated Interferon-α2b and Lamivudine in Hepatitis B e Antigen-Positive Chronic Hepatitis B. Ann Intern Med. 2005;143:391. doi: 10.7326/0003-4819-143-5-200509060-00018

Download citation file:

© 2018

×
Permissions

Published: Ann Intern Med. 2005;143(5):391.

DOI: 10.7326/0003-4819-143-5-200509060-00018

©
2005 American College of Physicians
1 Citations
CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2018 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×